Genor Biopharma Co., Ltd.

6 articles about Genor Biopharma Co., Ltd.

• 

  BioSpace Global Roundup, June 25

  6/25/2020

  Biopharma and life sciences companies provide updates on their pipelines and business plans.

• G1 Therapeutics and Genor Biopharma Announce Exclusive License Agreement for Lerociclib in Asia-Pacific Region

  6/22/2020

  G1 Therapeutics, Inc. and Genor Biopharma Co. Inc. announced an exclusive license agreement for the development and commercialization of lerociclib in the Asia-Pacific region.

• Genor Biopharma, a Pre-commercial Stage Biopharma Company, Announced the Appointment of Jack Hu as Chief Financial Officer and Chief Strategy Officer

  9/3/2019

  Before joining Genor, Dr. Hu served as Managing Director and Head of APAC Healthcare Research at Deutsche Bank, where he covered Asia/China healthcare.

• Ascentage Pharma Announces Strategic Collaboration with Genor Biopharma

  12/19/2018

  Collaboration to evaluate combination of APG-115, Ascentage's MDM2-p53 inhibitor and genolimzumab, Genor's anti-PD-1 monoclonal antibody in solid tumors and blood cancers

• CBT Pharmaceuticals Receives First Australian Ethics Approval to Initiate APOLLO-1 Phase 1/2 Clinical Trial for Hepatocellular and Renal Cell Carcinoma

  8/8/2018

  CBT Pharmaceuticals (CBT), a U.S. and China-based innovative biopharmaceutical company committed to becoming a leader in the discovery and development of oncology combination therapies, today announced the receipt of ethics approval from the Bellberry Human Research Ethics Committee (HREC) in Australia for its planned APOLLO-1 clinical trial.

• Genor Biopharma, Walvax’s, Partners With Mabspace Biosciences To Discover And Develop Novel Antibody Therapeutics

  5/21/2015